Personalized Medicine and Preventive Healthcare Sciences (Noritaka ARIYOSHI)

Personalized Medicine and Preventive Healthcare Sciences Noritaka ARIYOSHI, PhD

Major Areas of Research

1. Clinical study on an individualization approach to suppress postprandial hyperglycemia and related noncommunicable diseases
2. Clinical study on proper use of antiplatelet drugs in patients with acute coronary syndrome
3. Study on individual optimization of antiepileptic drugs using biomarkers
4. Study on individual optimization of cancer treatment based on expression levels of protein controlling pharmacokinetics

Current Research Interests

We are interested in an individual optimization of drug treatment because of the presence of a huge inter-individual difference in efficacy and adverse drug reaction. Therefore, we conduct both basic and clinical research to clarify the relationship between drug responsiveness and biological information using specimens such as human tissues. Moreover, the importance of preventive healthcare grows rapidly in Japan, since a population rate of elderly people has already exceeded more than 25%. Thus, we are investigating a viable individualized methods to prevent prelifestyle-related diseases including impaired glucose tolerance in humans by clinical intervention trials.

Selected Recent Publications

1.     Wakabayashi S, Ariyoshi N, Kitahara H, Fuji K, Fujimoto Y, Kobayashi Y. Efficacy of 2.5 mg of Prasugrel in Elderly patients or those with a Low Body-Weight. Circ J, in press

2.     San NS, Matsumoto J, Koike M, Saito Y, Sakaue H, Kato Y, Ariyoshi N, Yamada Y: Determination of sofosbuvir via a high-performance liquid chromatography method using ultraviolet detection. J Int Univ Health Welfare, 23, 130-136 (2018)

3.     Maekawa M, Mori M, Fujiyoshi M, Suzuki H, Yanai K, Noda A, Tanaka M, Takasaki S, Kikuchi M, Akasaka K, Kisara S, Matsuura M, Hisamichi K, Sato M, Goto J, Shimada M, Yamaguchi H, Mano N. A Direct Injection LC/ESI-MS/MS Analysis of Urinary Cyclophosphamide as an Anticancer Drug for Monitoring Occupational Exposure. Chromatography, 39, 41-47 (2018)

4.     Natori T, Fujiyoshi M, Uchida M, Abe N, Kanaki T, Fukumoto Y, Ishii I. Growth Arrest of Vascular Smooth Muscle Cells in Suspension Culture Using Low-Acyl Gellan Gum. In Vitro Cell Dev-An., 53, 191-198 (2017)

5.     Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Wakabayashi S, Hanaoka H, Kobayashi Y. Impact of Chronic Kidney Disease on Platelet Inhibition of Clopidogrel and Prasugrel in Japanese Patients. J. Cardiol. 69, 752-755 (2017)

6.     Wakabayashi S, Kitahara H, Nishi T, Sugimoto K, Nakayama T, Fujimoto Y, Ariyoshi N, Kobayashi Y. Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome. Cardiovasc Interv Ther. 2017 Jun 12. doi: 10.1007/s12928-017-0475-8. [Epub ahead of print]

7.     Kanogawa Y, Fujiyoshi M, Nakazato Y, Watanabe K, Kurihara M, Takezawa A, Uchida M, Igarashi K, Suzuki T, Ariyoshi N, Ishii I: Beta-migrating very low-density lipoprotein conjugates with acrolein in high-cholesterol diet-fed rabbits and localizes to atherosclerotic lesions with macrophages. Int J Clin Exp Pathol. 9, 11149-11158 (2016).

8.     Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takahara M, Wakabayashi S, Koshizaka M, Hanaoka H, Kobayashi Y. Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease. Circ J. 79, 2439-2444 (2015)

9.     Matsumoto J, Ariyoshi N, Sakakibara M, Nakanishi T, Okubo Y, Shiina N, Fujisaki K, Nagashima T, Nakatani Y, Tamai I, Yamada H, Takeda H, Ishii I. Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. Drug Metab Pharmacokinet, 30, 133-141 (2015)